GNPDA2: A Potential Drug Target and Biomarker (G132789)

Target Name: GNPDA2

NCBI ID: G132789

GNPDA2

GNPDA2: A Potential Drug Target and Biomarker

GNPDA2, or G-protein-coupled receptor type 2, is a protein that is expressed in various tissues and cells in the body. It is a member of the G protein-coupled receptor family, which is a large family of transmembrane proteins that play an important role in cellular signaling. GNPDA2 is one of the many G protein-coupled receptors that have been identified as potential drug targets in recent years.

The G protein-coupled receptor family is a large and diverse family of transmembrane proteins that play an important role in cellular signaling. These proteins are involved in a wide range of physiological processes, including sensory perception, neurotransmission, and hormone signaling. GNPDA2 is a member of this family and is expressed in various tissues and cells in the body.

GNPDA2 is a protein that is expressed in the brain, heart, kidneys, and other organs. It is involved in a wide range of physiological processes, including the regulation of pain, inflammation, and blood pressure. GNPDA2 is also involved in the regulation of the immune system and has been shown to play an important role in the regulation of allergic reactions.

GNPDA2 is a potential drug target because of its involvement in a wide range of physiological processes. For example, GNPDA2 has been shown to be involved in the regulation of pain, and drugs that block its activity may be effective in treating a variety of pain conditions. GNPDA2 is also involved in the regulation of inflammation and has been shown to play an important role in the regulation of neuroinflammation. These properties make GNPDA2 an attractive target for drug development.

In addition to its potential as a drug target, GNPDA2 is also a potential biomarker. The G protein-coupled receptor family is involved in a wide range of physiological processes, including sensory perception and neurotransmission. Therefore, changes in the level of GNPDA2 in certain tissues or cells may be an indication of certain diseases or conditions. For example, decreased levels of GNPDA2 in the brain may be an indication of neurodegenerative diseases, while increased levels of GNPDA2 in the kidneys may be an indication of kidney disease.

GNPDA2 is also a potential target for small molecules because of its high protein expression and stability. This makes it a good candidate for drug development using small molecules. Many small molecules have been shown to interact with GNPDA2 and have the potential to block its activity. This suggests that GNPDA2 may be an attractive target for small molecules that are used to treat a variety of diseases.

In conclusion, GNPDA2 is a protein that is expressed in various tissues and cells in the body and is involved in a wide range of physiological processes. Its potential as a drug target and biomarker make it an attractive target for drug development. The study of GNPDA2 and its potential drug development are an important area of research in the field of pharmacology.

Protein Name: Glucosamine-6-phosphate Deaminase 2

Functions: Catalyzes the reversible conversion of alpha-D-glucosamine 6-phosphate (GlcN-6P) into beta-D-fructose 6-phosphate (Fru-6P) and ammonium ion, a regulatory reaction step in de novo uridine diphosphate-N-acetyl-alpha-D-glucosamine (UDP-GlcNAc) biosynthesis via hexosamine pathway. Deamination is coupled to aldo-keto isomerization mediating the metabolic flux from UDP-GlcNAc toward Fru-6P. At high ammonium level can drive amination and isomerization of Fru-6P toward hexosamines and UDP-GlcNAc synthesis. Has a role in fine tuning the metabolic fluctuations of cytosolic UDP-GlcNAc and their effects on hyaluronan synthesis that occur during tissue remodeling

The "GNPDA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GNPDA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets